ASO Author Reflections: Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma in Patients with Impaired Liver Function: Is It Justified?
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Surgical Oncology"
DOI: 10.1245/s10434-020-08985-7
Abstract: Hepatectomy is a mainstay of curative treatment for hepatocellular carcinoma (HCC); however, impaired liver function due to underlying chronic liver disease often restricts curative treatment options, including hepatectomy. Major hepatectomy can lead to severe postoperative… read more here.
Keywords: hepatocellular carcinoma; liver function; liver; portal vein ... See more keywords
Independent Association of Serum Fibroblast Growth Factor 21 Levels With Impaired Liver Enzymes in Hyperthyroid Patients
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2018.00800
Abstract: Fibroblast growth factor 21 (FGF21) is identified as a potential biomarker for liver diseases. However, information is limited regarding serum FGF21 and impaired liver function in hyperthyroidism. We aim to determine the potential association of… read more here.
Keywords: serum fgf21; liver enzymes; impaired liver; hyperthyroid patients ... See more keywords
Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Biochemistry"
DOI: 10.5937/jomb0-38952
Abstract: Background The study aimed to estimate lidocaine (LID) pharmacokinetic parameter values in patients with impaired liver function, level of correlation between the pharmacokinetic parameters and Child-Pugh class and change in pharmacokinetic parameters after liver tumor… read more here.
Keywords: impaired liver; pharmacokinetic parameter; patients impaired; pharmacokinetic parameters ... See more keywords